Clarivate

Global Pharma And AI Trends Will Build Future Growth

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

11 May 25

AnalystConsensusTarget's Fair Value

US$5.14

29.8% undervalued

04 Sep

US$3.61

-46.5%

-4.5%

-46.5%

-4.5%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

US$5.1429.8% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$5.14

29.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.46%

Professional Services revenue growth rate

0.22%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

11.31%

Calculation

US$3.41m

Earnings '28

1167.87x

PE Ratio '28

US$3.98b

Market Cap '28

US$3.98b

Market Cap '28

569.55m

No. shares '28

US$6.99

Share Price '28

US$6.99 Share Price '28

Discounted to 2025 @ 10.80% p.a.

US$5.14

Fair Value '25